2022
American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan—2022 Update
Blonde L, Umpierrez GE, Reddy SS, McGill JB, Berga SL, Bush M, Chandrasekaran S, DeFronzo RA, Einhorn D, Galindo RJ, Gardner TW, Garg R, Garvey WT, Hirsch IB, Hurley DL, Izuora K, Kosiborod M, Olson D, Patel SB, Pop-Busui R, Sadhu AR, Samson SL, Stec C, Tamborlane WV, Tuttle KR, Twining C, Vella A, Vellanki P, Weber SL. American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan—2022 Update. Endocrine Practice 2022, 28: 923-1049. PMID: 35963508, PMCID: PMC10200071, DOI: 10.1016/j.eprac.2022.08.002.Peer-Reviewed Original ResearchConceptsClinical practice guidelinesEvidence-based recommendationsPractice guidelinesGlycemic targetsDiabetes mellitusComprehensive careCare plansEvidence-based clinical practice recommendationsEndocrinology Clinical Practice GuidelineNew evidence-based recommendationsLiterature searchManagement of prediabetesDiabetes care teamDiabetic kidney diseaseClinical practice recommendationsComprehensive care planType 1 diabetesAmerican AssociationCare of personsHealth care professionalsSecondary diabetesBariatric surgeryInsulin therapyClinical evidenceKidney diseaseSGLT2i Improves Glycemic Control in Patients With Congenital Severe Insulin Resistance.
Galderisi A, Tamborlane W, Taylor SI, Attia N, Moretti C, Barbetti F. SGLT2i Improves Glycemic Control in Patients With Congenital Severe Insulin Resistance. Pediatrics 2022, 150 PMID: 35652305, DOI: 10.1542/peds.2021-055671.Peer-Reviewed Original ResearchConceptsRabson-Mendenhall syndromeGlycemic controlHemoglobin A1cRenal calcium excretionInsulin-resistant diabetesSevere insulin resistanceCalcium excretionUrinary calciumAntidiabetic treatmentDay doseDose escalationSecond patientFirst patientInsulin levelsInsulin resistanceUrinary excretionSerum glucosePatientsEmpagliflozinMild increaseDapagliflozinΒ-hydroxybutyrateTarget rangeA1CExcretion
2021
Impact of Type 1 Diabetes in the Developing Brain in Children: A Longitudinal Study.
Mauras N, Buckingham B, White NH, Tsalikian E, Weinzimer SA, Jo B, Cato A, Fox LA, Aye T, Arbelaez AM, Hershey T, Tansey M, Tamborlane W, Foland-Ross LC, Shen H, Englert K, Mazaika P, Marzelli M, Reiss AL. Impact of Type 1 Diabetes in the Developing Brain in Children: A Longitudinal Study. Diabetes Care 2021, 44: 983-992. PMID: 33568403, PMCID: PMC7985430, DOI: 10.2337/dc20-2125.Peer-Reviewed Original ResearchConceptsType 1 diabetesBrain volumeControl subjectsTotal brain volume differencesEarly-onset type 1 diabetesAge-matched control subjectsIntelligence quotientCognitive scoresWhite matter volumeBrain volume differencesContinuous glucose monitoringDiabetes groupFull-scale intelligence quotientDiabetes complicationsDiabetes controlTotal brainVerbal intelligence quotientDiabetesMatter volumeSensor glucoseCognitive testingGlucose monitoringMixed-effects modelsBrainGroup differences
2020
Refractive Error and Retinopathy Outcomes in Type 1 Diabetes The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study
Hainsworth DP, Gao X, Bebu I, Das A, de Koo L, Barkmeier AJ, Tamborlane W, Lachin JM, Aiello LP, Group D. Refractive Error and Retinopathy Outcomes in Type 1 Diabetes The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study. Ophthalmology 2020, 128: 554-560. PMID: 32941962, PMCID: PMC7956062, DOI: 10.1016/j.ophtha.2020.09.014.Peer-Reviewed Original ResearchConceptsDiabetic macular edemaDiabetic retinopathyRefractive errorProliferative DRMacular edemaDiabetes controlDiabetes InterventionsRisk factorsUnadjusted modelsComplications Trial/EpidemiologyStages of DRCox proportional hazards modelDCCT treatment groupEDIC years 4Refractive error statusStandard fundus photographsAlbumin excretion rateDuration of diabetesIndependent risk factorDCCT/EDICDiastolic blood pressureSignificant macular edemaProliferative diabetic retinopathyPotential risk factorsProportional hazards modelAlcohol Use and Clinical Outcomes in Adults in the Type 1 Diabetes Exchange
Alessi SM, Foster NC, Rash CJ, Van Name MA, Tamborlane WV, Cengiz E, Polsky S, Wagner J. Alcohol Use and Clinical Outcomes in Adults in the Type 1 Diabetes Exchange. Canadian Journal Of Diabetes 2020, 44: 501-506. PMID: 32792103, DOI: 10.1016/j.jcjd.2020.06.005.Peer-Reviewed Original ResearchConceptsBody mass indexSevere hypoglycemiaFormer drinkersLower oddsAlcohol consumptionNonbinge drinkersType 1Current binge drinkersPresence of neuropathyDiabetes-related distressDiabetes-related outcomesType 1 diabetesCross-sectional studyYears of ageNon-Hispanic whitesDiabetic ketoacidosisRecent severe hypoglycemiaMedical chartsClinical outcomesMass indexProspective studyDiabetes distressBlood glucoseBinge drinkersDrinking statusEfficacy and Safety of Insulin Glargine 300 Units/mL (Gla-300) Versus Insulin Glargine 100 Units/mL (Gla-100) in Children and Adolescents (6–17 years) With Type 1 Diabetes: Results of the EDITION JUNIOR Randomized Controlled Trial
Danne T, Tamborlane WV, Malievsky OA, Franco DR, Kawamura T, Demissie M, Niemoeller E, Goyeau H, Wardecki M, Battelino T. Efficacy and Safety of Insulin Glargine 300 Units/mL (Gla-300) Versus Insulin Glargine 100 Units/mL (Gla-100) in Children and Adolescents (6–17 years) With Type 1 Diabetes: Results of the EDITION JUNIOR Randomized Controlled Trial. Diabetes Care 2020, 43: 1512-1519. PMID: 32430458, PMCID: PMC7305011, DOI: 10.2337/dc19-1926.Peer-Reviewed Original ResearchTime spent outside of target glucose range for young children with type 1 diabetes: a continuous glucose monitor study
DiMeglio LA, Kanapka LG, DeSalvo DJ, Anderson BJ, Harrington KR, Hilliard ME, Laffel LM, Tamborlane WV, Van Name MA, Wadwa RP, Willi SM, Woerner S, Wong JC, Miller KM, Group F. Time spent outside of target glucose range for young children with type 1 diabetes: a continuous glucose monitor study. Diabetic Medicine 2020, 37: 1308-1315. PMID: 32096282, PMCID: PMC9065795, DOI: 10.1111/dme.14276.Peer-Reviewed Original ResearchChildren and adolescents with type 1 and type 2 diabetes mellitus in the Pediatric Diabetes Consortium Registries: comparing clinical characteristics and glycaemic control
Van Name MA, Cheng P, Gal RL, Kollman C, Lynch J, Nelson B, Tamborlane WV, Consortium F. Children and adolescents with type 1 and type 2 diabetes mellitus in the Pediatric Diabetes Consortium Registries: comparing clinical characteristics and glycaemic control. Diabetic Medicine 2020, 37: 863-867. PMID: 31943374, DOI: 10.1111/dme.14233.Peer-Reviewed Original ResearchConceptsType 2 diabetesType 1 diabetesPediatric Diabetes ConsortiumTarget HbAType 1Median C-peptide levelsResidual endogenous insulin secretionType 2 diabetes mellitusC-peptide levelsEndogenous insulin secretionOverweight/obeseYears of agePoor diabetes outcomesSubset of participantsCharacteristics of childrenDiabetic ketoacidosisGlycaemic controlClinical characteristicsDiabetes mellitusDiabetes outcomesRisk factorsFamilies of childrenInsulin secretionInsulin treatmentDiabetes diagnosis
2019
“I'm essentially his pancreas”: Parent perceptions of diabetes burden and opportunities to reduce burden in the care of children <8 years old with type 1 diabetes
Commissariat PV, Harrington KR, Whitehouse AL, Miller KM, Hilliard ME, Van Name M, DeSalvo DJ, Tamborlane WV, Anderson BJ, DiMeglio LA, Laffel LM. “I'm essentially his pancreas”: Parent perceptions of diabetes burden and opportunities to reduce burden in the care of children <8 years old with type 1 diabetes. Pediatric Diabetes 2019, 21: 377-383. PMID: 31808586, PMCID: PMC7830825, DOI: 10.1111/pedi.12956.Peer-Reviewed Original ResearchConceptsType 1 diabetesGlycemic controlDiabetes burdenSecondary caregiversEmotional burdenChildren's glycemic controlYoung childrenCare of childrenAge 5.2Parents' perceptionsCaregivers' knowledgeClinical centersSemi-structured qualitative interviewsDiabetesDiabetes educationParental burdenHealthcare providersAge groupsInsulin pumpParents' burdenT1DChildren's qualityChild's diabetesParents' knowledgeParents' confidenceExecutive task-based brain function in children with type 1 diabetes: An observational study
Foland-Ross LC, Buckingam B, Mauras N, Arbelaez AM, Tamborlane WV, Tsalikian E, Cato A, Tong G, Englert K, Mazaika PK, Reiss AL. Executive task-based brain function in children with type 1 diabetes: An observational study. PLOS Medicine 2019, 16: e1002979. PMID: 31815939, PMCID: PMC6901178, DOI: 10.1371/journal.pmed.1002979.Peer-Reviewed Original ResearchConceptsType 1 diabetesExecutive control regionsFunctional magnetic resonance imagingT1D groupGlycemic controlBrain functionClinical disease courseDiabetes-related impairmentNon-diabetic controlsOptimal glycemic controlImproved glycemic controlNon-diabetic childrenActivation patternsMagnetic resonance imagingSuppression of activationDefault mode networkChronic dysglycemiaDisease courseGlycemic effectsT1D onsetPediatric T1DPosterior DMNFuture studiesBlood glucoseClinical assessmentGreater parental comfort with lower glucose targets in young children with Type 1 diabetes using continuous glucose monitoring
Van Name MA, Miller KM, Commissariat PV, Whitehouse AL, Harrington KR, Anderson BJ, Mantravadi MG, Levy W, DeSalvo DJ, Tamborlane WV, Hilliard ME, Laffel LM, DiMeglio LA. Greater parental comfort with lower glucose targets in young children with Type 1 diabetes using continuous glucose monitoring. Diabetic Medicine 2019, 36: 1508-1510. PMID: 31295359, PMCID: PMC7027357, DOI: 10.1111/dme.14074.Peer-Reviewed Original ResearchGlucose management for rewards: A randomized trial to improve glucose monitoring and associated self‐management behaviors in adolescents with type 1 diabetes
Wagner JA, Petry NM, Weyman K, Tichy E, Cengiz E, Zajac K, Tamborlane WV. Glucose management for rewards: A randomized trial to improve glucose monitoring and associated self‐management behaviors in adolescents with type 1 diabetes. Pediatric Diabetes 2019, 20: 997-1006. PMID: 31271239, PMCID: PMC6786915, DOI: 10.1111/pedi.12889.Peer-Reviewed Original ResearchConceptsType 1 diabetesWithdrawal of reinforcementImproved metabolic controlProportion of daysGroup differencesSelf-management behaviorsEffect sizeEUC participantsMean A1CUsual careWeek 24Week 12Blood glucoseGlucose managementWeek 6Metabolic controlAge groupsDiabetesGlucose monitoringBaselineSMBGDurable increaseWeeksA1CWithdrawalScreening eye exams in youth with type 1 diabetes under 18 years of age: Once may be enough?
Gubitosi‐Klug R, Bebu I, White NH, Malone J, Miller R, Lorenzi GM, Hainsworth DP, Trapani VR, Lachin JM, Tamborlane WV, Group* F. Screening eye exams in youth with type 1 diabetes under 18 years of age: Once may be enough? Pediatric Diabetes 2019, 20: 743-749. PMID: 31206973, PMCID: PMC7217664, DOI: 10.1111/pedi.12877.Peer-Reviewed Original ResearchConceptsYears of ageType 1 diabetesDiabetic retinopathyEye examEarly Treatment Diabetic Retinopathy Study (ETDRS) scaleMild non-proliferative diabetic retinopathyDiabetic Retinopathy Study scaleNon-proliferative diabetic retinopathyDiabetic retinopathy assessmentDiabetic retinopathy statusBaseline glycated hemoglobinClinical trial evidenceSignificant macular edemaProliferative diabetic retinopathyStandardized clinical trialsDiabetic retinopathy examinationsRetinopathy assessmentRetinopathy statusBaseline characteristicsComplications TrialMacular edemaCase seriesDiabetes controlIncident casesTrial evidenceBenefits and Barriers of Continuous Glucose Monitoring in Young Children with Type 1 Diabetes
Hilliard ME, Levy W, Anderson BJ, Whitehouse AL, Commissariat PV, Harrington KR, Laffel LM, Miller KM, Van Name M, Tamborlane WV, DeSalvo DJ, DiMeglio LA. Benefits and Barriers of Continuous Glucose Monitoring in Young Children with Type 1 Diabetes. Diabetes Technology & Therapeutics 2019, 21: 493-498. PMID: 31287721, PMCID: PMC6708264, DOI: 10.1089/dia.2019.0142.Peer-Reviewed Original ResearchConceptsContinuous glucose monitoringCGM useDiabetes managementDiabetes careBenefits of CGMYoung childrenGlucose monitoringMean child ageChildren's diabetes careType 1 diabetes managementPainful insertionT1D durationParents of childrenGlucose excursionsImproved sleepClinical strategiesSemistructured qualitative interviewsType 1Parental comfortChild's ageChildrenBehavioural supportMultiple barriersParents' experiencesCaregiversBiologic and social factors predict incident kidney disease in type 1 diabetes: Results from the T1D exchange clinic network
McGill JB, Wu M, Pop-Busui R, Mizokami-Stout K, Tamborlane WV, Aleppo G, Gubitosi-Klug RA, Haller MJ, Willi SM, Foster NC, Zimmerman C, Libman I, Polsky S, Rickels MR. Biologic and social factors predict incident kidney disease in type 1 diabetes: Results from the T1D exchange clinic network. Journal Of Diabetes And Its Complications 2019, 33: 107400. PMID: 31279735, DOI: 10.1016/j.jdiacomp.2019.06.005.Peer-Reviewed Original ResearchConceptsAdverse kidney outcomesDiabetic kidney diseaseKidney outcomesType 1 diabetesKidney diseaseRisk factorsRisk of DKDDevelopment of DKDT1D Exchange Clinic NetworkAlbumin/creatinine ratioIncident kidney diseaseBlood pressure controlModifiable risk factorsT1D Exchange RegistryUrine albumin measurementsLow education levelModern clinical practiceEGFR declineIncident albuminuriaT1D durationBaseline characteristicsSerum creatinineCreatinine ratioMajor complicationsHigher HbA1cEffect of Injection Site Cooling and Warming on Insulin Glargine Pharmacokinetics and Pharmacodynamics
Bitton G, Rom V, Hadelsberg U, Raz I, Cengiz E, Weinzimer S, Tamborlane WV. Effect of Injection Site Cooling and Warming on Insulin Glargine Pharmacokinetics and Pharmacodynamics. Journal Of Diabetes Science And Technology 2019, 13: 1123-1128. PMID: 31067999, PMCID: PMC6835184, DOI: 10.1177/1932296819842151.Peer-Reviewed Original ResearchConceptsInjection siteGlucose levelsSerum glucoseSubcutaneous depotMultiple daily insulin injectionsOvernight glucose levelsDaily insulin injectionsBlood glucose controlType 1 diabetesSensor glucose levelsInsulin infusion rateDL increaseInsulin glargineSerum insulinGlucose controlMDI therapyInsulin injectionsInsulin concentrationsPharmacodynamic studiesInfusion rateSkin warmingSeparate daysControl dayRate of absorptionRandom orderLiraglutide in Children and Adolescents with Type 2 Diabetes
Tamborlane WV, Barrientos-Pérez M, Fainberg U, Frimer-Larsen H, Hafez M, Hale PM, Jalaludin MY, Kovarenko M, Libman I, Lynch JL, Rao P, Shehadeh N, Turan S, Weghuber D, Barrett T. Liraglutide in Children and Adolescents with Type 2 Diabetes. New England Journal Of Medicine 2019, 381: 637-646. PMID: 31034184, DOI: 10.1056/nejmoa1903822.Peer-Reviewed Original ResearchConceptsGlycated hemoglobin levelsType 2 diabetesGastrointestinal adverse eventsAdverse eventsPlasma glucose levelsHemoglobin levelsEnd pointGlycemic controlGlucose levelsMean glycated hemoglobin levelOpen-label extension periodPrimary efficacy end pointDose of liraglutideDouble-blind periodEfficacy end pointPrimary end pointSecondary end pointsBody mass indexNumber of patientsYears of ageMetformin monotherapySubcutaneous liraglutidePlacebo groupLiraglutide groupInclusion criteriaContinuous Glucose Monitoring Profiles in Healthy Nondiabetic Participants: A Multicenter Prospective Study
Shah VN, DuBose SN, Li Z, Beck RW, Peters AL, Weinstock RS, Kruger D, Tansey M, Sparling D, Woerner S, Vendrame F, Bergenstal R, Tamborlane WV, Watson SE, Sherr J. Continuous Glucose Monitoring Profiles in Healthy Nondiabetic Participants: A Multicenter Prospective Study. The Journal Of Clinical Endocrinology & Metabolism 2019, 104: 4356-4364. PMID: 31127824, PMCID: PMC7296129, DOI: 10.1210/jc.2018-02763.Peer-Reviewed Original ResearchConceptsContinuous glucose monitoringMedian timeAge groupsProspective studyNondiabetic individualsGlucose levelsAverage glucoseNonobese body mass indexT1D Exchange Clinic NetworkContinuous glucose monitoring (CGM) profilesInsulin-requiring patientsMulticenter prospective studyBody mass indexDifferent age groupsNondiabetic childrenNondiabetic populationGlycemic profileMass indexNondiabetic participantsGlycemic variabilityMean glucoseClinic networkCGM metricsGlycemic metricsGlucose monitoringRisk Factors for Kidney Disease in Type 1 Diabetes
Perkins BA, Bebu I, de Boer IH, Molitch M, Tamborlane W, Lorenzi G, Herman W, White NH, Pop-Busui R, Paterson AD, Orchard T, Cowie C, Lachin JM, Group O. Risk Factors for Kidney Disease in Type 1 Diabetes. Diabetes Care 2019, 42: dc182062. PMID: 30833370, PMCID: PMC6489116, DOI: 10.2337/dc18-2062.Peer-Reviewed Original ResearchConceptsHigher systolic blood pressureHigher mean triglyceridesSystolic blood pressureRisk factorsKidney diseaseBlood pressureIncident macroalbuminuriaMean triglyceridesMultivariable Cox proportional hazards modelsGlomerular filtration rate lossCox proportional hazards modelComplications Trial (DCCT) cohortNonglycemic risk factorsModifiable risk factorsFrequency of screeningAssociation of baselineType 1 diabetesProportional hazards modelGlycemic exposureTrial cohortDiabetes controlMale sexHazards modelClinical strategiesAdvanced stageReversal of Ketosis in Type 1 Diabetes Is Not Adversely Affected by SGLT2 Inhibitor Therapy
Siebel S, Galderisi A, Patel NS, Carria LR, Tamborlane WV, Sherr JL. Reversal of Ketosis in Type 1 Diabetes Is Not Adversely Affected by SGLT2 Inhibitor Therapy. Diabetes Technology & Therapeutics 2019, 21: 101-104. PMID: 30688521, PMCID: PMC6434586, DOI: 10.1089/dia.2018.0356.Peer-Reviewed Original ResearchConceptsType 1 diabetesFree fatty acidsSGLT2i useAspart insulinSGLT2 inhibitor therapyPlasma glucose levelsSodium-glucose cotransporterCanagliflozin treatmentEuglycemic DKARescue therapyBasal insulinInhibitor therapyRate of ketogenesisRescue treatmentBlunted increaseSubcutaneous injectionGlucose levelsTreatment studiesNormal increaseInsulinDiabetesTherapyKetogenesisFatty acidsTreatment